Evidence map›Paper›PMID 40747226›Full record

ArticleWorld journal of hepatology2025

Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis.

Bo Zang, Jia-Xiu Li, Qi-Xuan Liu, Yuan Yao, Hua Li, Yan Wang, Ji-Gang Wang, Yi-Fei Yang, Rui-Wen Liang, Xin-Ran Xin and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo ZangDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Jia-Xiu LiDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Qi-Xuan LiuGraduate Group of Epidemiology, University of California Davis, Davis, CA 95616, United States.
Yuan YaoDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Hua LiDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Yan WangDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Ji-Gang WangDepartment of Pathology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Yi-Fei YangDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Rui-Wen LiangDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Xin-Ran XinDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China.
Bin LiuDepartment of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao 266001, Shandong Province, China. binliu72314@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pathogenesis of primary biliary cholangitis (PBC) remains unclear. Ursodeoxycholic acid (UDCA) is the only first-line clinical treatment, but approximately 40% of patients exhibit a poor response.

aimTo identify novel biomarkers for PBC to predict the efficacy of UDCA and enhance treatment.

methodsMicroarray expression profiling datasets were downloaded from the Gene Expression Omnibus and analyzed to identify differentially expressed genes between PBC patients and healthy controls. Immunohistochemistry was performed to validate key genes in liver tissues of the participants. Logistic regression was employed to evaluate prognostic risk factors, receiver operating characteristic curves were used to assess predictive performance, and correlations between key genes and clinicopathological characteristics were analyzed.

resultsBy bioinformatic analysis, 13 genes primarily associated with the progression of PBC were identified, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3) was selected for further investigation. Then expression of TNFAIP3 in PBC patients was significantly elevated compared to healthy controls on immunohistochemistry (

conclusionTNFAIP3 and fatigue are independent risk factors for response to UDCA in Chinese patients with PBC. TNFAIP3 may be a potential biomarker or therapeutic target for PBC. These findings offer new insights into the pathogenesis of PBC.

Indexed as

Bioinformatics analysisBiomarkersPredictorPrimary biliary cholangitisTherapeutic targetTumor necrosis factor alpha-induced protein 3

Identifiers

PMID40747226
PMCPMC12308571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.